Sangamo Therapeutics Stock Beta
| SGMO Stock | USD 0.56 0.02 3.70% |
Sangamo Therapeutics fundamentals help investors to digest information that contributes to Sangamo Therapeutics' financial success or failures. It also enables traders to predict the movement of Sangamo Stock. The fundamental analysis module provides a way to measure Sangamo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sangamo Therapeutics stock.
Sangamo | Beta |
Sangamo Therapeutics Company Beta Analysis
Sangamo Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Sangamo Therapeutics Beta | 1.35 |
Most of Sangamo Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangamo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sangamo Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Sangamo Therapeutics is extremely important. It helps to project a fair market value of Sangamo Stock properly, considering its historical fundamentals such as Beta. Since Sangamo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sangamo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sangamo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Sangamo Therapeutics has a Beta of 1.351. This is 57.09% higher than that of the Biotechnology sector and 2.81% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Sangamo Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sangamo Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sangamo Therapeutics could also be used in its relative valuation, which is a method of valuing Sangamo Therapeutics by comparing valuation metrics of similar companies.Sangamo Therapeutics is currently under evaluation in beta category among related companies.
Sangamo Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Sangamo Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sangamo Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sangamo Therapeutics' value.| Shares | Two Sigma Advisers, Llc | 2023-12-31 | 2.1 M | Jpmorgan Chase & Co | 2023-12-31 | 1.4 M | Long Focus Capital Management, Llc | 2023-12-31 | 1.4 M | Northern Trust Corp | 2023-12-31 | 1.3 M | Charles Schwab Investment Management Inc | 2023-12-31 | 1.2 M | Millennium Management Llc | 2023-12-31 | 1.1 M | Gsa Capital Partners Llp | 2023-12-31 | 1.1 M | Assenagon Asset Management Sa | 2023-12-31 | 1 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 909 K | Blackrock Inc | 2023-12-31 | 14.1 M | Vanguard Group Inc | 2023-12-31 | 12.6 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sangamo Therapeutics will likely underperform.
Sangamo Fundamentals
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (24.76) % | ||||
| Current Valuation | 56.41 M | ||||
| Shares Outstanding | 203.67 M | ||||
| Shares Owned By Insiders | 9.40 % | ||||
| Shares Owned By Institutions | 49.93 % | ||||
| Number Of Shares Shorted | 11.41 M | ||||
| Price To Earning | (15.31) X | ||||
| Price To Book | 1.35 X | ||||
| Price To Sales | 0.63 X | ||||
| Revenue | 176.23 M | ||||
| Gross Profit | (138.6 M) | ||||
| EBITDA | (92.1 M) | ||||
| Net Income | (257.83 M) | ||||
| Cash And Equivalents | 315.72 M | ||||
| Cash Per Share | 2.02 X | ||||
| Total Debt | 38.1 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 2.86 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (224.84 M) | ||||
| Short Ratio | 5.05 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Target Price | 3.5 | ||||
| Number Of Employees | 405 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 113.06 M | ||||
| Total Asset | 165.32 M | ||||
| Retained Earnings | (1.41 B) | ||||
| Working Capital | 46.6 M | ||||
| Current Asset | 212.58 M | ||||
| Current Liabilities | 20.1 M | ||||
| Net Asset | 165.32 M |
About Sangamo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangamo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangamo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangamo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink | |
| XLM | Stellar | |
| CRO | Cronos |
Check out Sangamo Therapeutics Piotroski F Score and Sangamo Therapeutics Altman Z Score analysis. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Sangamo Stock analysis
When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 1.01 | Quarterly Revenue Growth (0.93) | Return On Assets (0.18) | Return On Equity (1.36) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.